基因检测市场－全球产业规模、份额、趋势、机会及预测（按技术、应用、产品、通路、最终用户、地区和竞争格局划分，2021-2031年）

全球基因检测市场预计将从 2025 年的 93.1 亿美元成长到 2031 年的 185.8 亿美元，复合年增长率达到 12.21%。

该领域涉及对人类DNA、RNA、染色体、蛋白质和代谢物进行实验室分析，以检测与体细胞或遗传疾病相关的基因型、突变和表型。成长要素的关键因素包括全球慢性病盛行率的上升以及对个人化医疗日益增长的需求，而这需要识别准确的生物标记以优化治疗。美国癌症协会（ACS）预测，到2025年，美国将新增超过200万例癌症病例，这意味着庞大的患者群体需要进行基因组分析以製定有效的治疗方案。

儘管潜力巨大，但市场仍面临着充满挑战且不断变化的法规环境。检查室自建检测（LDT）的报销政策不一致，监管框架也不够明确，这可能会阻碍新型诊断检测方法的开发和商业化。这些监管障碍往往导致核准时间延长、合规成本增加，从而限制患者获得先进检测方案的机会，并阻碍现有和新兴市场参与者的收入成长。

市场驱动因素

肿瘤学领域基因检测的扩展是推动市场发展的关键因素，其主要驱动力来自精准医疗的转型和伴随诊断的需求。随着製药公司推出标靶治疗，对基因组分析以识别合格的患者的需求迅速增长，直接推动了诊断服务提供者检测量的成长。新治疗方法的核准进一步强化了这一趋势。根据 PharmaBoardroom 于 2025 年 5 月发布的报告，FDA 在 2024 年核准了七种新的细胞和基因疗法，显着提升了对精准基因检测的需求。液态生物检体和分子诊断领域的公司正经历着快速成长。例如，Guardant Health 报告称，在其截至 2025 年 10 月的财年中，其临床肿瘤检测量年增 40%，达到约 74,000 例。

同时，非侵入性产前检测 (NIPT) 的日益普及正将市场范围从肿瘤学扩展到生殖医学。无细胞 DNA 染色体异常筛检的广泛接受度正在革新产前护理，促使医疗服务提供者将这些安全、高通量的解决方案纳入常规诊疗流程。这种普及体现在各大实验室的营运规模上，它们正在处理创纪录数量的检体。 2025 年 11 月，Neatara 报告称，其第三季度处理了约 893,600 份检测样本，比去年同期增长 15.2%，这凸显了临床和生殖健康保健领域对基因筛检的强烈依赖和日益增长的趋势。

市场挑战

复杂多变的监管环境和不一致的报销政策对全球基因检测市场的扩张构成了重大障碍。这种环境为实验室带来了不确定性，因为严格的合规要求延长了核准流程，尤其对于检查室自建检测（LDT）更是如此。支付方监管不力且严格的报销限制显着增加了诊断服务提供者的行政负担。这些障碍扼杀了创新，阻碍了新型检测方法的商业化。企业面临营运成本上升和收入延迟到帐的困境，而官僚主义的障碍也使得将个人化医疗的需求转化为实际检测量变得困难。

近期数据证实了这些医保覆盖障碍的实际影响：美国医学会 (AMA) 2024 年的报告显示，94% 的受访医生表示，事先核准流程会延误患者获得治疗。这种行政上的繁琐程序会延长诊断时间，并常常导致检测中止，从而直接减少基因组分析的实施数量，并限制市场参与企业的收入潜力。

市场趋势

将人工智慧 (AI) 和机器学习 (ML) 整合到基因组数据分析中，正在从根本上改变市场运作方式。随着定序通量的提高，产生的数据量已超过人工分析能力，因此自动化解决方案对于变异分类和解读至关重要。这项技术使实验室能够扩展其生物资讯流程，同时加快週转时间并提高复杂报告的准确性。这种应用的商业性价值显而易见。在英伟达 (NVIDIA) 于 2025 年 7 月发布的题为「医疗保健和生命科学领域人工智慧现状：2025 年趋势」的调查中，超过 80% 的医疗保健和生命科学专业人士表示，人工智慧促进了其所在机构的收入增长，凸显了计算工具对财务绩效的重要性。

同时，针对健康人群的预防性基因组筛检正在将市场拓展至症状患者之外。医疗系统正从被动诊断转向主动人群健康管理，利用大规模定序在症状出现之前检测出遗传性癌症、心血管疾病和其他疾病的风险因素。支持这一转变的是将基因组学见解融入基层医疗的大型跨机构合作。例如，2025年2月，TriHealth宣布与Helix合作，启动一项精准人群健康管理倡议，目标是在五年内覆盖10万名参与者，这展现了预防性基因数据的规模化应用。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球基因检测市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 按技术（次世代定序、晶片技术、基于PCR的检测）
  • 按用途分类（祖籍与民族、性状筛检、遗传疾病带原者状态、新生儿筛检、健康与保健 - 倾向/风险/易感性）
  • 依产品分类（耗材、设备、软体及服务）
  • 依销售管道（线上、线下）
  • 依最终使用者（医院/诊所、诊断检查室、其他）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美基因检测市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲基因检测市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区基因检测市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲基因检测市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章 南美洲基因检测市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球基因检测市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• 24Genetics SL
• Prenetics Global Limited
• Circle DNA
• TellmeGen
• 23andMe, Inc.
• AncestryDNA
• myDNA Life Australia Pty Ltd.
• Myriad Genetics, Inc.
• MapmyGenome
• MyHeritage Ltd.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Genetic Testing Market is projected to expand from USD 9.31 Billion in 2025 to USD 18.58 Billion by 2031, achieving a compound annual growth rate of 12.21%. This sector involves the laboratory analysis of human DNA, RNA, chromosomes, proteins, or metabolites to detect genotypes, mutations, or phenotypes associated with somatic or heritable conditions. Key growth drivers include the rising global prevalence of chronic disorders and the increasing demand for personalized medicine, which requires precise biomarker identification for tailored treatments. According to the American Cancer Society, projections for 2025 estimated over 2 million new cancer diagnoses in the United States, indicating a vast patient pool necessitating genomic profiling for effective treatment planning.

Despite this potential, the market contends with a challenging and shifting regulatory environment. Inconsistent reimbursement policies and ambiguous oversight frameworks for Laboratory Developed Tests can hinder the creation and commercialization of new diagnostic assays. These regulatory barriers often lead to prolonged approval times and higher compliance costs, restricting patient access to advanced testing solutions and limiting revenue growth for both established and emerging market players.

Market Driver

The growing use of genetic testing in oncology is a major market force, driven by the shift toward precision medicine and the necessity for companion diagnostics. As pharmaceutical companies introduce targeted therapies, the need for genomic profiling to identify eligible patients has surged, directly increasing test volumes for diagnostic providers. This trend is reinforced by the approval of new treatments; PharmaBoardroom noted in May 2025 that the FDA approved seven new cell and gene therapies in 2024, creating significant demand for precise genetic assays. Companies in liquid biopsy and molecular diagnostics are seeing utilization spikes; for example, Guardant Health's October 2025 financial results reported a 40% year-over-year increase in clinical oncology test volumes, reaching approximately 74,000 tests.

Simultaneously, the rising adoption of Non-Invasive Prenatal Testing (NIPT) is extending market reach beyond oncology into reproductive health. The broad acceptance of cell-free DNA screening for chromosomal abnormalities has revolutionized prenatal care, prompting providers to make these safe, high-throughput solutions a routine part of practice. This adoption is reflected in the scale of operations at leading laboratories, which are handling record sample numbers. Natera reported in November 2025 that it processed roughly 893,600 tests during the third quarter, a 15.2% increase from the prior year, highlighting the strong and increasing reliance on genetic screening for clinical and reproductive needs.

Market Challenge

A complex and evolving regulatory landscape, along with inconsistent reimbursement policies, creates a significant barrier to the Global Genetic Testing Market's expansion. This environment generates uncertainty for laboratories, especially regarding Laboratory Developed Tests, by enforcing strict compliance requirements that lengthen approval timelines. When oversight is unclear or payers apply rigid coverage restrictions, the administrative burden on diagnostic providers grows substantially. These obstacles stifle innovation and deter the commercialization of new assays, as companies face increased operational costs and delayed revenue, causing the market to struggle in converting the demand for personalized medicine into actual testing volumes due to bureaucratic impediments.

Recent data confirms the operational impact of these coverage barriers. In 2024, the American Medical Association reported that 94% of surveyed physicians experienced delays in patient access to care due to prior authorization processes. Such administrative friction prolongs diagnosis times and often results in test abandonment, directly lowering the number of genomic profiles conducted and restricting the revenue potential for both established and emerging participants in the market.

Market Trends

The integration of Artificial Intelligence and Machine Learning into genomic data interpretation is fundamentally changing market operations. As sequencing throughput grows, the resulting data volume surpasses manual analysis capacities, requiring automated solutions for variant classification and interpretation. This technology enables laboratories to scale bioinformatic pipelines, shortening turnaround times for complex reports while improving accuracy. The commercial value of this adoption is clear; in a July 2025 survey by NVIDIA titled 'State of AI in Healthcare and Life Sciences: 2025 Trends', over 80% of healthcare and life sciences professionals indicated that AI contributed to revenue growth at their organizations, emphasizing the importance of computational tools for financial performance.

At the same time, a shift toward preventive genomic screening in healthy populations is widening the market beyond symptomatic patients. Health systems are moving from reactive diagnostics to proactive population health management, using large-scale sequencing to detect risk factors for conditions like hereditary cancer and cardiovascular disease before symptoms appear. Major institutional partnerships are supporting this transition to integrate genomic insights into primary care. For example, TriHealth announced in February 2025 a partnership with Helix to launch a precision population health initiative aiming to enroll 100,000 participants over five years, demonstrating the growing scale of preventive genetic data utilization.

Key Market Players

• 24Genetics SL
• Prenetics Global Limited
• Circle DNA
• TellmeGen
• 23andMe, Inc.
• AncestryDNA
• myDNA Life Australia Pty Ltd.
• Myriad Genetics, Inc.
• MapmyGenome
• MyHeritage Ltd.

Report Scope

In this report, the Global Genetic Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Genetic Testing Market, By Technology

• Next Generation Sequencing
• Array Technology
• PCR-based Testing

Genetic Testing Market, By Application

• Ancestry & Ethnicity
• Traits Screening
• Genetic Disease Carrier Status
• New Baby Screening
• Health & Wellness-Predisposition/Risk/Tendency

Genetic Testing Market, By Product

• Consumables
• Equipment
• Software & Services

Genetic Testing Market, By Channel

• Online
• Offline

Genetic Testing Market, By End User

• Hospitals & Clinics
• Diagnostic Laboratories
• Others

Genetic Testing Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Genetic Testing Market.

Available Customizations:

Global Genetic Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Genetic Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technology (Next Generation Sequencing, Array Technology, PCR-based Testing)
  • 5.2.2. By Application (Ancestry & Ethnicity, Traits Screening, Genetic Disease Carrier Status, New Baby Screening, Health & Wellness-Predisposition/Risk/Tendency)
  • 5.2.3. By Product (Consumables, Equipment, Software & Services)
  • 5.2.4. By Channel (Online, Offline)
  • 5.2.5. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
  • 5.2.6. By Region
  • 5.2.7. By Company (2025)
• 5.3. Market Map

6. North America Genetic Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technology
  • 6.2.2. By Application
  • 6.2.3. By Product
  • 6.2.4. By Channel
  • 6.2.5. By End User
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Genetic Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technology
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By Product
      • 6.3.1.2.4. By Channel
      • 6.3.1.2.5. By End User
  • 6.3.2. Canada Genetic Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technology
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By Product
      • 6.3.2.2.4. By Channel
      • 6.3.2.2.5. By End User
  • 6.3.3. Mexico Genetic Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technology
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By Product
      • 6.3.3.2.4. By Channel
      • 6.3.3.2.5. By End User

7. Europe Genetic Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technology
  • 7.2.2. By Application
  • 7.2.3. By Product
  • 7.2.4. By Channel
  • 7.2.5. By End User
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Genetic Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technology
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Product
      • 7.3.1.2.4. By Channel
      • 7.3.1.2.5. By End User
  • 7.3.2. France Genetic Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technology
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Product
      • 7.3.2.2.4. By Channel
      • 7.3.2.2.5. By End User
  • 7.3.3. United Kingdom Genetic Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technology
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Product
      • 7.3.3.2.4. By Channel
      • 7.3.3.2.5. By End User
  • 7.3.4. Italy Genetic Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technology
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By Product
      • 7.3.4.2.4. By Channel
      • 7.3.4.2.5. By End User
  • 7.3.5. Spain Genetic Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technology
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By Product
      • 7.3.5.2.4. By Channel
      • 7.3.5.2.5. By End User

8. Asia Pacific Genetic Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technology
  • 8.2.2. By Application
  • 8.2.3. By Product
  • 8.2.4. By Channel
  • 8.2.5. By End User
  • 8.2.6. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Genetic Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technology
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Product
      • 8.3.1.2.4. By Channel
      • 8.3.1.2.5. By End User
  • 8.3.2. India Genetic Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technology
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Product
      • 8.3.2.2.4. By Channel
      • 8.3.2.2.5. By End User
  • 8.3.3. Japan Genetic Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technology
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Product
      • 8.3.3.2.4. By Channel
      • 8.3.3.2.5. By End User
  • 8.3.4. South Korea Genetic Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Technology
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By Product
      • 8.3.4.2.4. By Channel
      • 8.3.4.2.5. By End User
  • 8.3.5. Australia Genetic Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Technology
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By Product
      • 8.3.5.2.4. By Channel
      • 8.3.5.2.5. By End User

9. Middle East & Africa Genetic Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technology
  • 9.2.2. By Application
  • 9.2.3. By Product
  • 9.2.4. By Channel
  • 9.2.5. By End User
  • 9.2.6. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Genetic Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technology
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Product
      • 9.3.1.2.4. By Channel
      • 9.3.1.2.5. By End User
  • 9.3.2. UAE Genetic Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technology
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Product
      • 9.3.2.2.4. By Channel
      • 9.3.2.2.5. By End User
  • 9.3.3. South Africa Genetic Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Product
      • 9.3.3.2.4. By Channel
      • 9.3.3.2.5. By End User

10. South America Genetic Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technology
  • 10.2.2. By Application
  • 10.2.3. By Product
  • 10.2.4. By Channel
  • 10.2.5. By End User
  • 10.2.6. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Genetic Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technology
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By Product
      • 10.3.1.2.4. By Channel
      • 10.3.1.2.5. By End User
  • 10.3.2. Colombia Genetic Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technology
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By Product
      • 10.3.2.2.4. By Channel
      • 10.3.2.2.5. By End User
  • 10.3.3. Argentina Genetic Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technology
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By Product
      • 10.3.3.2.4. By Channel
      • 10.3.3.2.5. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Genetic Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. 24Genetics SL
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Prenetics Global Limited
• 15.3. Circle DNA
• 15.4. TellmeGen
• 15.5. 23andMe, Inc.
• 15.6. AncestryDNA
• 15.7. myDNA Life Australia Pty Ltd.
• 15.8. Myriad Genetics, Inc.
• 15.9. MapmyGenome
• 15.10. MyHeritage Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer